CN101736062B - 一种重组猪α干扰素标准品的制备方法 - Google Patents
一种重组猪α干扰素标准品的制备方法 Download PDFInfo
- Publication number
- CN101736062B CN101736062B CN2009101856564A CN200910185656A CN101736062B CN 101736062 B CN101736062 B CN 101736062B CN 2009101856564 A CN2009101856564 A CN 2009101856564A CN 200910185656 A CN200910185656 A CN 200910185656A CN 101736062 B CN101736062 B CN 101736062B
- Authority
- CN
- China
- Prior art keywords
- porcine alpha
- interferon
- substratum
- alpha
- standard substance
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000126 substance Substances 0.000 title claims abstract description 40
- 108010047761 Interferon-alpha Proteins 0.000 title claims abstract description 33
- 102000006992 Interferon-alpha Human genes 0.000 title claims abstract description 33
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000000855 fermentation Methods 0.000 claims abstract description 7
- 230000004151 fermentation Effects 0.000 claims abstract description 7
- 238000000746 purification Methods 0.000 claims abstract description 7
- 238000000751 protein extraction Methods 0.000 claims abstract description 5
- 102000014150 Interferons Human genes 0.000 claims description 58
- 108010050904 Interferons Proteins 0.000 claims description 58
- 229940079322 interferon Drugs 0.000 claims description 58
- 238000004587 chromatography analysis Methods 0.000 claims description 38
- 241000894006 Bacteria Species 0.000 claims description 33
- 238000005215 recombination Methods 0.000 claims description 31
- 230000006798 recombination Effects 0.000 claims description 31
- 239000007788 liquid Substances 0.000 claims description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 16
- 239000012153 distilled water Substances 0.000 claims description 15
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 14
- 230000001580 bacterial effect Effects 0.000 claims description 14
- 238000010828 elution Methods 0.000 claims description 14
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 238000010521 absorption reaction Methods 0.000 claims description 12
- 239000012148 binding buffer Substances 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 12
- 239000000243 solution Substances 0.000 claims description 12
- 239000011780 sodium chloride Substances 0.000 claims description 10
- 239000000203 mixture Substances 0.000 claims description 9
- 239000002808 molecular sieve Substances 0.000 claims description 9
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 9
- 206010010254 Concussion Diseases 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- 238000004140 cleaning Methods 0.000 claims description 6
- 230000009514 concussion Effects 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 5
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 4
- 238000011081 inoculation Methods 0.000 claims description 4
- 229910052760 oxygen Inorganic materials 0.000 claims description 4
- 239000001301 oxygen Substances 0.000 claims description 4
- 239000006228 supernatant Substances 0.000 claims description 4
- FRXSZNDVFUDTIR-UHFFFAOYSA-N 6-methoxy-1,2,3,4-tetrahydroquinoline Chemical compound N1CCCC2=CC(OC)=CC=C21 FRXSZNDVFUDTIR-UHFFFAOYSA-N 0.000 claims description 3
- 241000588724 Escherichia coli Species 0.000 claims description 3
- 238000001042 affinity chromatography Methods 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 239000012149 elution buffer Substances 0.000 claims description 3
- 239000013613 expression plasmid Substances 0.000 claims description 3
- 150000002460 imidazoles Chemical class 0.000 claims description 3
- 238000005374 membrane filtration Methods 0.000 claims description 3
- 238000012856 packing Methods 0.000 claims description 3
- 238000003556 assay Methods 0.000 abstract description 2
- 230000004071 biological effect Effects 0.000 abstract 1
- 230000006698 induction Effects 0.000 abstract 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 21
- 241000700605 Viruses Species 0.000 description 15
- 239000000047 product Substances 0.000 description 13
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 241000711975 Vesicular stomatitis virus Species 0.000 description 9
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
- 238000004448 titration Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 7
- 239000012530 fluid Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 108090000790 Enzymes Proteins 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000013016 damping Methods 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 238000000926 separation method Methods 0.000 description 5
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000003292 glue Substances 0.000 description 4
- 244000144972 livestock Species 0.000 description 4
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 125000003275 alpha amino acid group Chemical group 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 239000012362 glacial acetic acid Substances 0.000 description 3
- 238000009413 insulation Methods 0.000 description 3
- 238000004321 preservation Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000959794 Homo sapiens Interferon alpha-2 Proteins 0.000 description 2
- 102100040018 Interferon alpha-2 Human genes 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 2
- YVNQAIFQFWTPLQ-UHFFFAOYSA-O [4-[[4-(4-ethoxyanilino)phenyl]-[4-[ethyl-[(3-sulfophenyl)methyl]amino]-2-methylphenyl]methylidene]-3-methylcyclohexa-2,5-dien-1-ylidene]-ethyl-[(3-sulfophenyl)methyl]azanium Chemical compound C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C(=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=2C(=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S(O)(=O)=O)C)C=C1 YVNQAIFQFWTPLQ-UHFFFAOYSA-O 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000009360 aquaculture Methods 0.000 description 2
- 244000144974 aquaculture Species 0.000 description 2
- 230000001174 ascending effect Effects 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 230000005611 electricity Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 206010048282 zoonosis Diseases 0.000 description 2
- 101710081722 Antitrypsin Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000190596 Latino mammarenavirus Species 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 208000027954 Poultry disease Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- PMZXXNPJQYDFJX-UHFFFAOYSA-N acetonitrile;2,2,2-trifluoroacetic acid Chemical compound CC#N.OC(=O)C(F)(F)F PMZXXNPJQYDFJX-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000001475 anti-trypsic effect Effects 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000003161 proteinsynthetic effect Effects 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002277 temperature effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Landscapes
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101856564A CN101736062B (zh) | 2009-11-27 | 2009-11-27 | 一种重组猪α干扰素标准品的制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2009101856564A CN101736062B (zh) | 2009-11-27 | 2009-11-27 | 一种重组猪α干扰素标准品的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101736062A CN101736062A (zh) | 2010-06-16 |
CN101736062B true CN101736062B (zh) | 2012-11-07 |
Family
ID=42460092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2009101856564A Active CN101736062B (zh) | 2009-11-27 | 2009-11-27 | 一种重组猪α干扰素标准品的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101736062B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108845144A (zh) * | 2017-12-05 | 2018-11-20 | 安徽九川生物科技有限公司 | 一种猪干扰素α生物学活性检测方法 |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103592441B (zh) * | 2013-10-29 | 2015-06-17 | 王明丽 | 一种重组猪干扰素ɑ双抗体夹心法免疫胶体金检测试纸条的制备方法 |
CN103589769B (zh) * | 2013-10-29 | 2016-06-29 | 王明丽 | 一种重组猪干扰素α1基因工程菌的高密度发酵方法 |
CN103589768A (zh) * | 2013-10-29 | 2014-02-19 | 赵俊 | 一种适用于高密度发酵生产重组猪干扰素α1的培养基 |
CN105755008A (zh) * | 2014-12-17 | 2016-07-13 | 北京大北农科技集团股份有限公司动物医学研究中心 | 编码猪α干扰素的DNA分子及其重组蛋白的表达纯化方法 |
CN105039474A (zh) * | 2015-08-25 | 2015-11-11 | 安徽九川生物科技有限公司 | 一种重组鸡干扰素α标准品的制备方法 |
CN106362140A (zh) * | 2016-08-25 | 2017-02-01 | 芜湖英特菲尔生物制品产业研究院有限公司 | 一种重组猪il‑2成品冻干制剂的制备方法 |
CN106367422A (zh) * | 2016-08-29 | 2017-02-01 | 安徽九川生物科技有限公司 | 一种重组羊干扰素τ生物学活性检测用标准品的制备方法 |
CN110734490A (zh) * | 2019-11-28 | 2020-01-31 | 苏州华研医用科技有限公司 | 重组人金属硫蛋白ⅲ纯品的制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289666A (zh) * | 2008-03-28 | 2008-10-22 | 王明丽 | 重组猪α型干扰素的制备方法 |
CN101434958A (zh) * | 2008-12-22 | 2009-05-20 | 浙江大学 | 一种制备猪α-干扰素的方法 |
-
2009
- 2009-11-27 CN CN2009101856564A patent/CN101736062B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101289666A (zh) * | 2008-03-28 | 2008-10-22 | 王明丽 | 重组猪α型干扰素的制备方法 |
CN101434958A (zh) * | 2008-12-22 | 2009-05-20 | 浙江大学 | 一种制备猪α-干扰素的方法 |
Non-Patent Citations (1)
Title |
---|
韩森.猪_干扰素基因的原核表达及活性分析.《浙江大学硕士学位论文》.2007,全文. * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108845144A (zh) * | 2017-12-05 | 2018-11-20 | 安徽九川生物科技有限公司 | 一种猪干扰素α生物学活性检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN101736062A (zh) | 2010-06-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101736062B (zh) | 一种重组猪α干扰素标准品的制备方法 | |
CN102229939A (zh) | 一种优化的高活性人溶菌酶基因及其表达载体和应用 | |
CN106148303A (zh) | 一种人源溶菌酶蛋白发酵方法 | |
CN106282279A (zh) | 一种重组犬干扰素α标准品、其制备方法及效价测定方法 | |
CN104788568A (zh) | 一种毕赤酵母菌基因工程杂合抗菌肽cc29及其获得方法 | |
CN103467584A (zh) | 一种原核基因工程杂合阳离子抗菌肽cc的获得及其发酵方法 | |
CN115109131A (zh) | 一种多克隆抗体在制备鉴别微孢子虫试剂中的应用 | |
CN102321631B (zh) | 人工合成鸡干扰素基因序列及其重组工程菌的构建与应用 | |
CN101450961B (zh) | 人工合成的猪干扰素基因及制备猪干扰素的方法 | |
CN103450355A (zh) | 重组牛alpha干扰素及其应用 | |
CN106367422A (zh) | 一种重组羊干扰素τ生物学活性检测用标准品的制备方法 | |
CN103059122B (zh) | 一种重组猪干扰素α1及其编码基因和表达方法 | |
CN102220364A (zh) | 一种家蝇抗菌肽Cecropin A的制备方法 | |
CN101955942B (zh) | 编码猪α-干扰素的DNA分子和重组大肠杆菌及其应用 | |
CN103589769B (zh) | 一种重组猪干扰素α1基因工程菌的高密度发酵方法 | |
CN103012578B (zh) | 一种重组猪白细胞介素2及其编码基因和表达方法 | |
CN101182475B (zh) | 高效表达弹性蛋白酶的毕赤酵母及其构建方法和应用 | |
CN102898512B (zh) | 一种重组菌丝霉素及其制备方法和用途 | |
CN102010867A (zh) | 重组中华蜜蜂王浆主蛋白AccMRJP1的酵母表达方法及产物用途 | |
CN102732436A (zh) | 截短的细粒棘球蚴eg95蛋白重组毕赤酵母高密度发酵工艺 | |
CN102816815A (zh) | 重组抗菌肽rCrustinI的酵母发酵生产方法 | |
CN101531967B (zh) | 一种生产α干扰素的方法及其专用菌 | |
CN101434958A (zh) | 一种制备猪α-干扰素的方法 | |
CN103725735A (zh) | 一种从短小芽孢杆菌e14中分离抗菌蛋白质的方法 | |
CN102978214B (zh) | 鸡-γ-干扰素基因序列,其重组工程菌及应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160413 Address after: 241009 Anhui province Wuhu Branch Center D Park Economic and Technological Development Zone No. 102, 101 Patentee after: Anhui JiuChuan Biotechnology Co., Ltd. Address before: 230032 Department of Microbiology, Medical University Of Anhui, 81 Mei Shan Road, Anhui, Hefei Patentee before: Wang Mingli Patentee before: Zhao Jun |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20160621 Address after: 241009 Anhui province Wuhu Branch Center D Park Economic and Technological Development Zone No. 102, 101 Patentee after: Anhui JiuChuan Biotechnology Co., Ltd. Patentee after: Wuhu Phil Biological Products Industry Research Institute Co. Ltd. Address before: 241009 Anhui province Wuhu Branch Center D Park Economic and Technological Development Zone No. 102, 101 Patentee before: Anhui JiuChuan Biotechnology Co., Ltd. |